Abstract
N-glycosylation, driven by the cis -prenyltransferase ( cis -PT) complex, a NUS1 and DHDDS heterotetramer, is vital for proteome integrity. Despite being linked to severe congenital disorders of glycosylation (CDGs), the systemic role of NUS1/DHDDS remains elusive. Here, we characterize the conserved C. elegans cis -PT complex and uncover a critical crosstalk with global lipid metabolism. cis -PT deficiency induces catastrophic ER stress, global glycoprotein defects, and developmental failure. Mechanistically, NUS-1 physically interacts with the core oligosaccharyltransferase (OST) complex, directly coupling substrate synthesis to N-glycan transfer. Loss of NUS-1 or DHDDS causes systemic lipopenia, lysosomal dysfunction, and cholesterol sequestration, resulting from impaired N-glycosylation of key regulatory glycoproteins like SCAP. Utilizing CDG-associated CRISPR models, we resolve the molecular basis for cis -PT dysfunction, identifying interface disruption and catalytic impairment as distinct disease etiologies. These findings collectively reveal a critical and previously unappreciated crosstalk between protein glycosylation and global lipid metabolism, establishing a robust system to explore CDG pathology and therapeutic strategies.
Full text
1,337 characters
· extracted from
oa-doi-fallback
· click to expand
Abstract
N-glycosylation, driven by the cis-prenyltransferase (cis-PT) complex, a NUS1 and DHDDS heterotetramer, is vital for proteome integrity. Despite being linked to severe congenital disorders of glycosylation (CDGs), the systemic role of NUS1/DHDDS remains elusive. Here, we characterize the conserved C. elegans cis-PT complex and uncover a critical crosstalk with global lipid metabolism. cis-PT deficiency induces catastrophic ER stress, global glycoprotein defects, and developmental failure. Mechanistically, NUS-1 physically interacts with the core oligosaccharyltransferase (OST) complex, directly coupling substrate synthesis to N-glycan transfer. Loss of NUS-1 or DHDDS causes systemic lipopenia, lysosomal dysfunction, and cholesterol sequestration, resulting from impaired N-glycosylation of key regulatory glycoproteins like SCAP. Utilizing CDG-associated CRISPR models, we resolve the molecular basis for cis-PT dysfunction, identifying interface disruption and catalytic impairment as distinct disease etiologies. These findings collectively reveal a critical and previously unappreciated crosstalk between protein glycosylation and global lipid metabolism, establishing a robust system to explore CDG pathology and therapeutic strategies.
Competing Interest Statement
The authors have declared no competing interest.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.